Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Ra...
Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial
About this item
Full title
Author / Creator
Publisher
United States: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Lung injury in COVID-19 is characterized by neutrophil invasion and the release of neutrophil extracellular traps (NETs). An aberrant NET formation may induce local inflammation and increase sputum viscosity. Inhalation of DNase I (dornase alfa) is a treatment option that degrades NETs in the airways. Previous case series have indicated positive cl...
Alternative Titles
Full title
Aerosolized Dornase Alfa (DNase I) for the Treatment of Severe Respiratory Failure in COVID-19: A Randomized Controlled Trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1093_ofid_ofaf246
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1093_ofid_ofaf246
Other Identifiers
ISSN
2328-8957
E-ISSN
2328-8957
DOI
10.1093/ofid/ofaf246
